Suppr超能文献

磷酸二酯酶4抑制剂激活慢性淋巴细胞白血病细胞中的线粒体凋亡途径,该途径受蛋白磷酸酶2A调控。

PDE4 inhibitors activate a mitochondrial apoptotic pathway in chronic lymphocytic leukemia cells that is regulated by protein phosphatase 2A.

作者信息

Moon Eun-Yi, Lerner Adam

机构信息

Evans Department of Medicine, Section of Hematology and Oncology, Boston Medical Center, Boston, MA, USA.

出版信息

Blood. 2003 May 15;101(10):4122-30. doi: 10.1182/blood-2002-10-3208. Epub 2003 Jan 16.

Abstract

Chronic lymphocytic leukemia (CLL) cells, but not peripheral blood T cells, undergo apoptosis following treatment with inhibitors of type 4 cyclic nucleotide phosphodiesterase (PDE4), a process that correlates dose dependently with elevation of adenosine 3',5'-cyclic monophosphate (cAMP) in leukemic cells. We show that treatment of CLL cells with rolipram, a prototypic PDE4 inhibitor, and forskolin, an adenylate cyclase activator, induces mitochondrial depolarization, release of cytochrome c into the cytosol, caspase-9 and -3 activation, and cleavage of poly(adenosine diphosphate [ADP]-ribose)polymerase. Inhibitors of caspase-9, but not caspase-8, block rolipram/forskolin-induced CLL apoptosis. In a subset of CLL patients, B-cell lymphoma 2 (Bcl-2)-associated death promoter homolog (Bad), a proapoptotic Bcl-2 family member that when phosphorylated on specific serine residues is sequestered in the cytosol by 14-3-3, was dephosphorylated at Ser112 following rolipram/forskolin treatment of leukemic cells. Rolipram/forskolin treatment also induced Bad to accumulate in CLL heavy-membrane fractions, consistent with Bad translocation to mitochondria. To determine the mechanism for rolipram/forskolin-induced Bad dephosphorylation, we examined CLL phosphatase activity. Rolipram/forskolin treatment augmented protein phosphatase 2A (PP2A) activity, as well as levels of immunoreactive PP2A catalytic subunit. Treatment of CLL cells with a concentration of okadaic acid (5 nM) that selectively inhibits PP2A, reduced both rolipram/forskolin-induced mitochondrial cytochrome c release and mitochondrial depolarization. Okadaic acid restored Bad Ser112 phosphorylation and Bad association with 14-3-3 in rolipram/forskolin-treated CLL cells. These results suggest that PDE4 inhibitors may induce CLL apoptosis by activating PP2A-induced dephosphorylation of proapoptotic BH3-only Bcl-2 family members such as Bad.

摘要

慢性淋巴细胞白血病(CLL)细胞在用4型环核苷酸磷酸二酯酶(PDE4)抑制剂处理后会发生凋亡,而外周血T细胞则不会,这一过程与白血病细胞中3',5'-环磷酸腺苷(cAMP)升高呈剂量依赖性相关。我们发现,用原型PDE4抑制剂咯利普兰和腺苷酸环化酶激活剂福斯高林处理CLL细胞,会诱导线粒体去极化、细胞色素c释放到胞质溶胶中、半胱天冬酶-9和-3激活以及聚(二磷酸腺苷[ADP]-核糖)聚合酶的裂解。半胱天冬酶-9抑制剂而非半胱天冬酶-8抑制剂可阻断咯利普兰/福斯高林诱导的CLL凋亡。在一部分CLL患者中,促凋亡的Bcl-2家族成员B细胞淋巴瘤2(Bcl-2)相关死亡促进因子同源物(Bad)在特定丝氨酸残基上磷酸化后会被14-3-3隔离在胞质溶胶中,在白血病细胞经咯利普兰/福斯高林处理后,其Ser112位点发生去磷酸化。咯利普兰/福斯高林处理还诱导Bad在CLL重膜组分中积累,这与Bad转位至线粒体一致。为确定咯利普兰/福斯高林诱导Bad去磷酸化的机制,我们检测了CLL磷酸酶活性。咯利普兰/福斯高林处理增强了蛋白磷酸酶2A(PP2A)活性以及免疫反应性PP2A催化亚基的水平。用选择性抑制PP2A的冈田酸浓度(5 nM)处理CLL细胞,可降低咯利普兰/福斯高林诱导的线粒体细胞色素c释放和线粒体去极化。冈田酸恢复了咯利普兰/福斯高林处理的CLL细胞中Bad Ser112位点的磷酸化以及Bad与14-3-3的结合。这些结果表明,PDE4抑制剂可能通过激活PP2A诱导的促凋亡仅含BH3结构域的Bcl-2家族成员(如Bad)去磷酸化来诱导CLL凋亡。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验